Jill E. Urquhart

Jill E. Urquhart

Auto-generated profile, based on publicly available information

Jill E. Urquhart

Genetic Medicine Research Group, Manchester Biomedical Research Centre, Manchester Academic Health Sciences Centre, University of Manchester and Central Manchester Foundation Trust, St Mary's Hospital, Manchester M13 9WL, UK

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2008 in The American Journal of Human Genetics
Verified
Journal Article
Closed access
RBRosemary Burgess
Rosemary Burgess
IMIan D. Millar
Ian D. Millar
BLBart P. Leroy
Bart P. Leroy
JUJill E. Urquhart
Jill E. Urquhart
IFIan M. Fearon
Ian M. Fearon
GBGraeme Black
Graeme Black

1 April 2013 in The American Journal of Human Genetics
Verified
Journal Article
Closed access
EJEmma M. Jenkinson
Emma M. Jenkinson
ARAtteeq U. Rehman
Atteeq U. Rehman
TWTomas Walsh
Tomas Walsh
JCJill Clayton-Smith
Jill Clayton-Smith
KLKwanghyuk Lee
Kwanghyuk Lee
WNWilliam Newman
William Newman

22 January 2012 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
BABeverley H Anderson
Beverley H Anderson
PKPaul Kasher
Paul Kasher
JMJosephine Mayer
Josephine Mayer
MSMarcin Szynkiewicz
Marcin Szynkiewicz
EJEmma M Jenkinson
Emma M Jenkinson
YCYanick J Crow
Yanick J Crow

9 January 2011 in Nature Genetics
Verified
Journal Article
Open access
PDF file
TBTracy A Briggs
Tracy A Briggs
GRGillian I Rice
Gillian I Rice
SDSarah Daly
Sarah Daly
JUJill Urquhart
Jill Urquhart
HGHannah Gornall
Hannah Gornall
YCYanick J Crow
Yanick J Crow
Yanick Crow and colleagues show that mutations in ACP5, which encodes tartrate-resistant acid phosphatase, cause spondyloenchondrodysplasia, a bone dysplasia with autoimmunity. The affected individuals had elevated serum interferon alpha activity. We studied ten individuals from eight families showing features consistent with the immuno-osseous dysplasia spondyloenchondrodysplasia. Of particular note was the diverse spectrum of autoimmune phenotypes observed in these individuals (cases), including systemic lupus erythematosus, Sjögren's syndrome, hemolytic anemia, thrombocytopenia, hypothyroidism, inflammatory myositis, Raynaud's disease and vitiligo. Haplotype data indicated the disease gene to be on chromosome 19p13, and linkage analysis yielded a combined multipoint log10 odds (LOD) score of 3.6. Sequencing of ACP5, encoding tartrate-resistant acid phosphatase, identified biallelic mutations in each of the cases studied, and in vivo testing confirmed a loss of expressed protein. All eight cases assayed showed elevated serum interferon alpha activity, and gene expression profiling in whole blood defined a type I interferon signature. Our findings reveal a previously unrecognized link between tartrate-resistant acid phosphatase activity and interferon metabolism and highlight the importance of type I interferon in the genesis of autoimmunity.

10 May 2013 in Arthritis & Rheumatism
Verified
Journal Article
Open access
PDF file
ABAlexandre Belot
Alexandre Belot
PKPaul Kasher
Paul Kasher
ETEleanor W. Trotter
Eleanor W. Trotter
AFAnne‐Perrine Foray
Anne‐Perrine Foray
ADAnne‐Laure Debaud
Anne‐Laure Debaud
Nathalie BonnefoyNathalie Bonnefoy
Nathalie Bonnefoy
Objective: Systemic lupus erythematosus (SLE) is a prototype autoimmune disease that is assumed to occur via a complex interplay of environmental and genetic factors. Rare causes of monogenic SLE have been described, providing unique insights into fundamental mechanisms of immune tolerance. The aim of this study was to identify the cause of an autosomal‐recessive form of SLE.Methods: We studied 3 siblings with juvenile‐onset SLE from 1 consanguineous kindred and used next‐generation sequencing to identify mutations in the disease‐associated gene. We performed extensive biochemical, immunologic, and functional assays to assess the impact of the identified mutations on B cell biology.Results: We identified a homozygous missense mutation in PRKCD, encoding protein kinase δ (PKCδ), in all 3 affected siblings. Mutation of PRKCD resulted in reduced expression and activity of the encoded protein PKCδ (involved in the deletion of autoreactive B cells), leading to resistance to B cell receptor– and calcium‐dependent apoptosis and increased B cell proliferation. Thus, as for mice deficient in PKCδ, which exhibit an SLE phenotype and B cell expansion, we observed an increased number of immature B cells in the affected family members and a developmental shift toward naive B cells with an immature phenotype.Conclusion: Our findings indicate that PKCδ is crucial in regulating B cell tolerance and preventing self‐reactivity in humans, and that PKCδ deficiency represents a novel genetic defect of apoptosis leading to SLE.

1 May 2011 in The American Journal of Human Genetics
Verified
Journal Article
Closed access
JOJames O'SUllivan
James O'SUllivan
CBCarolina C. Bitu
Carolina C. Bitu
SDSarah B. Daly
Sarah B. Daly
JUJill E. Urquhart
Jill E. Urquhart
MBMartin J. Barron
Martin J. Barron
MDMichael J. Dixon
Michael J. Dixon